BPC-157: frequently asked questions, answered from the literature.

A synthetic 15-amino-acid peptide (pentadecapeptide) derived from a protein found in human gastric juice. Its full name is Body Protection Compound 157. It has a molecular weight of 1,419.5 daltons and is stable in the gastric environment. Most of the research literature was generated in the 1993-2026 period by the Sikiric laboratory in Zagreb, with a small but growing body of independent replication.

In rodent studies, BPC-157 upregulates VEGFR2 expression and activates the VEGFR2-Akt-eNOS signaling pathway, driving angiogenesis and nitric oxide production.^[1] It also disrupts the Caveolin-1/eNOS inhibitory complex^[2] and upregulates growth hormone receptor in fibroblasts via JAK2.^[3] These three mechanisms are the most thoroughly characterized in the literature. In human subjects, no validated mechanism study has been conducted.

Animal research covers tendon and ligament healing,^[4][5] muscle repair,^[6] spinal cord injury recovery,^[7] hippocampal ischemia neuroprotection,^[8] cardiac cytoprotection,^[9] hepatoprotection,^[10] colocutaneous fistula healing,^[11] and multi-tissue wound healing.^[12] Human pilot data exists for interstitial cystitis^[20] and chronic knee pain^[16] — both small, uncontrolled, and preliminary.

Body Protection Compound-157. The number identifies it as the 157th amino acid sequence screened in the original Sikiric laboratory gastric protein fractionation work in the early 1990s.

The three primary proposed mechanisms are: VEGFR2 upregulation and angiogenesis promotion;^[1] disruption of the Caveolin-1/eNOS inhibitory complex, releasing nitric oxide production;^[2] and growth hormone receptor upregulation in fibroblasts via JAK2, amplifying local GH-driven tissue repair.^[3] Broader modulation of prostaglandin and all three NOS isoforms has also been documented.^[7][15]

Animal studies report no lethal dose in any published study and no serious organ toxicity.^[12] Three small human pilot studies (total enrollment approximately 26 subjects) reported no adverse events.^[16][20] No large-scale human safety trial has been conducted. The primary theoretical concern is VEGFR2-driven angiogenesis in oncological contexts, which is an active debate in the literature.^[18]

No. BPC-157 has no FDA-approved indication and holds no IND status. It is classified as an unapproved new drug in the United States. The FDA has issued warnings about peptide products sold outside the drug approval process. Human use is not authorized by the FDA.

Legal status varies by jurisdiction. In the United States, BPC-157 cannot be legally sold for human use; it is an unapproved drug. In competitive sport, it is prohibited under WADA S0 regardless of jurisdiction.

Yes. BPC-157 is listed on the WADA Prohibited List under S0 (Non-Approved Substances), prohibited at all times in- and out-of-competition. USADA has sanctioned athletes for its use, including a one-year ban for a speed skater in 2024 and a four-year ban for a volleyball player. No Therapeutic Use Exemption is available.

No. BPC-157 is a peptide — a short amino acid chain — with no steroidal ring structure. It does not bind androgen, estrogen, or glucocorticoid receptors. It is classified as a pentadecapeptide (15 amino acids) derived from gastric protein.

No. BPC-157 is a 15-amino-acid pentadecapeptide, not a 191-amino-acid pituitary hormone. One study found BPC-157 upregulates growth hormone receptor in tendon fibroblasts,^[3] amplifying the response to GH when GH is present — a receptor-sensitizing effect, not direct GH secretion or elevation of circulating growth hormone.

In the most detailed published pharmacokinetic study, elimination half-life was 15.2 minutes in rats (IV) and 5.27 minutes in beagle dogs (IV).^[19] Intramuscular bioavailability ranged from 14-51% depending on species. The short plasma half-life contrasts with durable tissue effects — suggesting receptor or gene-expression mechanisms outlast the circulating peptide. No validated human pharmacokinetic study has been published.

Rodent studies report measurable tissue repair acceleration within 7-14 days of daily dosing in tendon, ligament, and muscle models.^[4][6] In neurological models, functional recovery was observed within 24-72 hours of a single local application.^[8] No validated human timeline data exists.

In rodent studies, oral (gavage and drinking-water) administration of BPC-157 has shown efficacy in gastrointestinal models^[11] and ligament healing^[4] at the same dose levels as intraperitoneal injection. Whether systemic tissue-repair effects from oral dosing match IP injection in musculoskeletal or neurological models has not been directly compared in published literature.

Published research protocols dissolve lyophilized BPC-157 in bacteriostatic water, typically at 1-2 mg/mL. The peptide is reported to remain stable when refrigerated for several weeks. This describes standard laboratory methodology as documented in published methods sections, not a protocol for human use.

Animal studies have not shown nephrotoxicity. A 2025 ischemia-reperfusion study found BPC-157-treated rats showed significantly lower renal injury scores compared to untreated injury controls, with restored antioxidant enzyme activity.^[13] No validated human renal safety data exists.

Rodent cardiac models show cardioprotective effects: BPC-157 at 10 μg/kg IP counteracted myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis in multiple rat models.^[9] No adverse cardiac signals have been published in the animal literature. Human cardiac safety has not been evaluated.

Published animal studies show hepatoprotective effects: BPC-157 prevented hepatic necrosis and fatty change and normalized AST/ALT in CCl4, bile duct ligation, restraint-stress, and alcohol-induced liver injury models in rats.^[10] No hepatotoxic signal has been published in the BPC-157 animal literature.

No published in vivo study has shown BPC-157 promotes tumor growth. The VEGFR2 upregulation and pro-angiogenic mechanism raises a theoretical concern in oncological contexts — angiogenesis supports tumor vascularization. This is an active debate in the literature: the Sikiric group has cited anti-tumor data;^[18] the concern raised by Jozwiak et al. (2025) remains scientifically unresolved.

Not as a direct anabolic agent. BPC-157 consistently accelerates recovery after muscle injury in rodent models — crush-injury^[6] and myotendinous junction dissection^[14] — producing full fiber regeneration and functional restoration. No study has examined direct muscle anabolism in healthy uninjured animals.

No dedicated weight-loss studies exist in the BPC-157 literature. Metabolic recovery after toxic organ injury has been observed in hepatoprotection models,^[10] but these address toxic-insult recovery, not body composition or fat loss. No study has examined BPC-157 in a healthy-subject weight management context.

No direct androgenic action has been identified in the BPC-157 literature. The GHR upregulation mechanism involves fibroblast-level sensitization to growth hormone,^[3] not testosterone elevation. No study has documented changes in circulating testosterone in BPC-157-treated animals.

For BPC-157 specifically: the primary theoretical concern is pro-angiogenic VEGFR2 upregulation in oncological contexts; unknown long-term effects; and the absence of validated human pharmacokinetic and safety data. More broadly, unregulated peptide preparations carry unknown purity and sterility risks, and off-target receptor interactions have not been systematically characterized for most research peptides.

Human co-administration protocols do not exist in the published literature. Some rodent studies have combined both peptides and observed effects exceeding either alone, consistent with non-overlapping mechanisms — BPC-157 targeting angiogenesis and local GHR sensitization; TB-500 targeting systemic actin sequestration and cell migration. Both are prohibited under WADA S0 at all times.

The preclinical record is large, internally consistent, and covers multiple tissue types. Effect sizes in animal studies are consistently large. Human data is sparse — three small pilot studies, no completed large-scale RCT, and no published Phase II results. BPC-157 is not FDA-approved, carries a WADA prohibition, and the oncological safety debate remains unresolved. The evidence base is substantive but preliminary.^[16][17]